Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussed the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
The discussion highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Stewart, MD, summarized the key takeaways from the discussion.
Case Study
Stewart described an 83-year-old woman with diabetic macular edema (DME) who had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Author's summary: Anti-VEGF agents improve retinal disease treatment.
More News
- How GenAI Became a Disruptive Force in CS Higher Education – Communications of the ACM
- Founding partner Microsoft to bring new Discovery AI technology to NJ AI Hub
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Bridging public health, building design at UW’s Sustainability Symposium
- Secukinumab Looks Promising for Polymyalgia Rheumatica
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Palestine 36 review: an engaging historical drama
- Squad Busters will shut down in 2026 after struggling to meet Supercell's expectations
- The real test for Sussan Ley isn’t cancel culture
- Danielle Smith: Balancing the budget gets a lot easier if you build a pipeline